Immunostimulatory effect of thalidomide in normal C57BL/6 mice is compatible with stimulation of a highly connected central immune system.
Although thalidomide has been used with success in the treatment of increasing numbers of autoimmune diseases, the therapeutic effects have not been satisfactorily explained so far. We describe here some findings that may contribute to a better understanding of the immunomodulatory effects of this drug. Several immunological changes were observed after treating C57BL/6 mice with 3 mg of thalidomide. The numbers of natural IgM PFC against sheep red blood cells were increased in the spleen, and occasionally a dramatic oscillatory increase in the numbers of non-specific splenic IgM and IgG PFC was observed in these mice. However, these oscillatory increases were progressively lower, after two and three treatments with thalidomide at 20-day intervals. Furthermore, the absolute numbers of splenic CD5+ B and CD5- B lymphocytes were increased whereas depletion of CD4+ CD8+ cells in the thymus and of lymphoid cells in the bone marrow was seen after a single treatment with 3 mg of thalidomide. Taken together, these results suggest that thalidomide stimulates both peripheral and central immune systems and consequently enhances the connectivity of the central immune system.
Arala-Chaves
M
M
Department of Immunology, Institute for Biomedical Sciences Abel Salazar, Porto, Portugal.
Vilanova
M
M
Ribeiro
A
A
Pinto
J
J
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D015703:Antigens, CD / Q000187:drug effects; D001327:Autoimmune Diseases / Q000188:drug therapy; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018956:CD5 Antigens; D005434:Flow Cytometry; D006462:Hemolytic Plaque Technique; D007107:Immune System / Q000187:drug effects*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D013154:Spleen / Q000166:cytology; D013792:Thalidomide / Q000494:pharmacology*
D015703:Antigens, CD; D018956:CD5 Antigens; D013792:Thalidomide